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A B S T R A C T
Background
Melanoma accounts for a small proportion of all skin cancer cases but is responsible for most skin cancer-related deaths. Early detection
and treatment can improve survival. Smartphone applications are readily accessible and potentially offer an instant risk assessment of
the likelihood of malignancy so that the right people seek further medical attention from a clinician for more detailed assessment of
the lesion. There is, however, a risk that melanomas will be missed and treatment delayed if the application reassures the user that their
lesion is low risk.
Objectives
To assess the diagnostic accuracy of smartphone applications to rule out cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants in adults with concerns about suspicious skin lesions.
Search methods
We undertook a comprehensive search of the following databases from inception to August 2016: Cochrane Central Register of
Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing
Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials
Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies of any design evaluating smartphone applications intended for use by individuals in a community setting who have lesions
that might be suspicious for melanoma or atypical intraepidermal melanocytic variants versus a reference standard of histological
confirmation or clinical follow-up and expert opinion.
1Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on
QUADAS-2). Due to scarcity of data and poor quality of studies, we did not perform a meta-analysis for this review. For illustrative
purposes, we plotted estimates of sensitivity and specificity on coupled forest plots for each application under consideration.
Main results
This review reports on two cohorts of lesions published in two studies. Both studies were at high risk of bias from selective participant
recruitment and high rates of non-evaluable images. Concerns about applicability of findings were high due to inclusion only of lesions
already selected for excision in a dermatology clinic setting, and image acquisition by clinicians rather than by smartphone app users.
We report data for five mobile phone applications and 332 suspicious skin lesions with 86 melanomas across the two studies. Across the
four artificial intelligence-based applications that classified lesion images (photographs) as melanomas (one application) or as high risk
or ’problematic’ lesions (three applications) using a pre-programmed algorithm, sensitivities ranged from 7% (95% CI 2% to 16%) to
73% (95% CI 52% to 88%) and specificities from 37% (95% CI 29% to 46%) to 94% (95% CI 87% to 97%). The single application
using store-and-forward review of lesion images by a dermatologist had a sensitivity of 98% (95% CI 90% to 100%) and specificity of
30% (95% CI 22% to 40%).
The number of test failures (lesion images analysed by the applications but classed as ’unevaluable’ and excluded by the study authors)
ranged from 3 to 31 (or 2% to 18% of lesions analysed). The store-and-forward application had one of the highest rates of test failure
(15%). At least one melanoma was classed as unevaluable in three of the four application evaluations.
Authors’ conclusions
Smartphone applications using artificial intelligence-based analysis have not yet demonstrated sufficient promise in terms of accuracy,
and they are associated with a high likelihood of missing melanomas. Applications based on store-and-forward images could have a
potential role in the timely presentation of people with potentially malignant lesions by facilitating active self-management health
practices and early engagement of those with suspicious skin lesions; however, they may incur a significant increase in resource and
workload. Given the paucity of evidence and low methodological quality of existing studies, it is not possible to draw any implications
for practice. Nevertheless, this is a rapidly advancing field, and new and better applications with robust reporting of studies could
change these conclusions substantially.
P L A I N L A N G U A G E S U M M A R Y
How accurate are smartphone applications (’apps’) for detecting melanoma in adults?
What is the aim of the review?
We wanted to find out how well smartphone applications can help the general public understand whether their skin lesions might be
melanoma.
Why is improving the diagnosis of malignant melanoma skin cancer important?
Melanoma is one of the most dangerous forms of skin cancer. Not recognising a melanoma (a false negative test result) could delay
seeking appropriate advice and surgery to remove it. This increases the risk of the cancer spreading to other organs in the body and
possibly causing death. Diagnosing a skin lesion as a melanoma when it is not present (a false positive result) may cause anxiety and
lead to unnecessary surgery and further investigations.
What was studied in the review?
Specialised applications (’apps’) that provide advice on skin lesions or moles that might cause people concern are widely available for
smartphones. Some apps allow people to photograph any skin lesion they might be worried about and then receive guidance on whether
to get medical advice. Apps may automatically classify lesions as high or low risk, while others can act as store-and-forward devices
where images are sent to an experienced professional, such as a dermatologist, who then makes a risk assessment based on the photo.
Cochrane researchers found two studies, evaluating five apps that used automated analysis of images and one that used a store-and-
forward approach, to evaluate suspicious skin lesions.
What are the main results of the review?
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The review included two studies with 332 lesions, including 86 melanomas, analysed by at least one smartphone application. Both
studies used photographs of moles or skin lesions that were about to be removed because doctors had already decided they could be
melanomas. The photographs were taken by doctors instead of people taking pictures of their lesions with their own smartphones. For
these reasons, we are not able to make a reliable estimate about how well the apps actually work.
Four apps that produce an immediate (automated) assessment of a skin lesion or mole that has been photographed by the smartphone
missed between 7 and 55 melanomas.
One app that sends the photograph of a mole or skin lesion to a dermatologist for assessment missed only one melanoma. Another 6
melanomas examined by the dermatologist via the application were not classified as high risk; instead the dermatologist was not able
to classify the lesion as either ’atypical’ (possibly a melanoma) or ’typical’ (definitely not a melanoma).
How reliable are the results of the studies of this review?
The small number and poor quality of included studies reduces the reliability of findings. The people included were not typical of
those who would use the applications in real life. The final diagnosis of melanoma was made by histology, which is likely to have been
a reliable method for deciding whether patients really had melanoma*. However, the studies excluded between 2% and 18% of images
because the applications failed to produce a recommendation.
Who do the results of this review apply to?
Studies took place in the USA and Germany. They did not report key patient information such as age and gender. The percentage of
people with a final diagnosis of melanoma was 18% and 35%, much higher than that observed in community settings. The definition
of eligible patients was narrow in comparison to likely users of the applications. The photographs used were taken by doctors rather
than by smartphone users, which seriously impacts the applicability of results.
What are the implications of this review?
Current smartphone applications using automated analysis are observed to have a high chance of missing melanomas (false negatives).
Store-and-forward image applications could have a potential role in the timely identification of people with potentially malignant
lesions by facilitating early engagement of those with suspicious skin lesions, but they have resource and workload implications.
The development of applications to help identify people who might have melanoma is a fast-moving field. The emergence of new
applications, higher quality and better reported studies could change the conclusions of this review substantially.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy was the reference standard (means of establishing final diagnoses).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question What is the diagnostic accuracy of smartphone applications for detecting cutaneous melanoma in adults?
Part icipants Adults with suspicious skin lesions
Prior test ing and preva-
lence
Studies did not report the basis for part icipant select ion. One selected a sample of lesions previously imaged during rout ine care just before excision
of the lesion. The second study evaluated the test on pat ients who had been referred for further screening of the lesion by a specialist . Prevalence of
melanoma was 18% and 35%
Sett ings Secondary care
Target condit ion(s) Invasive melanoma and atypical intraepidermal melanocyt ic variants
Index test Smartphone applicat ions intended for use by the general public. Lesions not visualised by applicat ions excluded
Reference standard Histology
Act ion If accurate, posit ive results of smartphone applicat ions will help to highlight lesions of concern to the lay public, promoting earlier diagnosis of
melanoma and reducing consultat ions for benign lesions
Limitations
Risk of bias Patient select ion methods at high risk of bias due to select ive inclusion of lesion types (2/ 2) and use of a case-control design (1/ 2). Test interpretat ion
was blinded to reference standard and pre-specif ied for art if icial intelligence-based diagnosis (2/ 2). Reference standard blinding not described.
Tim ing of index and reference standards not reported. Exclusions due to test failures were not reported (1/ 2) or their f inal diagnoses were not
described (2/ 2)
Applicability of evi-
dence to quest ion
High concerns about applicability due to unrepresentat ive part icipant samples with high disease prevalences (2/ 2). Test not applied and interpreted
by the intended user of the applicat ion (2/ 2). Reference standard interpretat ion by experienced histopathologists was not described (1/ 2)
Total number of studies:2
Detection of melanoma
Quantity of evidence Number of studies 2 Total part icipants with test
results
332 Total with target condit ion 86a
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Findings Across the four art if icial intelligence-based applicat ions that classif ied lesion images (photographs) as either melanomas (one applicat ion) or as
high risk or ’problematic’ lesions (three applicat ions), sensit ivit ies ranged f rom 7% (95% CI 2% to 16%) to 73% (95% CI 52% to 88%) and specif icit ies
f rom 37% (95% CI 29% to 46%) to 94% (95% CI 87% to 97%). This means that between 27% and 93% of invasive melanoma or atypical intraepidermal
melanocyt ic variants were not picked up as high risk by the automated applicat ions (or as melanomas by one of the four applicat ions). With a
prevalence of melanoma ranging between 18% and 37% for these evaluat ions, the number of melanomas missed was 7 to 55
The single applicat ion using store-and-forward review of lesion images by a dermatologist had a sensit ivity of 98% (95% CI 90% to 100%) and
specif icity of 30% (95%CI 22% to 40%); the dermatologist m issed one melanoma
The number of test failures (lesion images analysed by the applicat ions but classed as unevaluable and excluded by the study authors) ranged f rom 3
to 31 (or 2% to 18% of lesions analysed). The store-and-forward applicat ion had one of the highest rates of test failure (15%). At least one melanoma
was classed as unevaluable in three of the four applicat ion evaluat ions, the highest number of melanomas excluded by the dermatologist evaluat ing
the store-and-forward images (6/ 60 melanomas assessed)
aOf the 60 melanomas included in one study, the four applicat ions successfully analysed 54 to 60.
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B A C K G R O U N D
This is one of a series of Cochrane Diagnostic Test Accuracy
(DTA) Reviews on the diagnosis and staging of melanoma and
keratinocyte skin cancers as part of the National Institute for
Health Research (NIHR) Cochrane Systematic Reviews Pro-
gramme. Appendix 1 shows the content and structure of the pro-
gramme. Appendix 2 provides a glossary of terms used.
Target condition being diagnosed
Melanoma arises from uncontrolled proliferation of melanocytes
- the epidermal cells that produce pigment or melanin (
Thompson 2003). Melanoma can occur in any organ that con-
tains melanocytes, including mucosal surfaces, the back of the
eye, and lining around the spinal cord and brain (McLaughlin
2005), but it most commonly arises in the skin (Erdmann 2013;
Ferlay 2015). Cutaneous melanoma refers to any skin lesion with
malignant melanocytes present in the dermis and includes super-
ficial spreading, nodular, acral lentiginous, and lentigo maligna
melanoma variants (see Figure 1). Melanoma in situ refers to ma-
lignant melanocytes that are contained within the epidermis and
have not yet invaded the dermis, but which are at risk of pro-
gression to melanoma if left untreated (Thompson 2003; SEER
2007). Lentigo maligna, a subtype of melanoma in situ in chron-
ically sun-damaged skin, denotes another form of proliferation
of abnormal melanocytes. Lentigo maligna can progress to inva-
sive melanoma if its growth breaches the dermo-epidermal junc-
tion during a vertical growth phase (when it becomes known as
’lentigo maligna melanoma’); however, its malignant transforma-
tion is both lower and slower than for melanoma in situ (Kasprzak
2015). Melanoma in situ and lentigo maligna are both atypi-
cal intraepidermal melanocytic variants (Thompson 2003; SEER
2007). Melanoma is one of the most dangerous forms of skin can-
cer, with the potential to metastasise to other parts of the body
via the lymphatic system and blood stream; it accounts for only a
small percentage of all skin cancer cases but is responsible for up
to 75% of skin cancer deaths (Boring 1994; Cancer Research UK
2017a).
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Figure 1. Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right).
Copyright © 2010 Dr Rubeta Matin: reproduced with permission.
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The annual incidence of melanoma exceeded 200,000 newly di-
agnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015),
with an estimated 55,000 deaths (Ferlay 2015). The highest inci-
dence is observed in Australia with 13,134 new cases of melanoma
of the skin in 2014 (ACIM 2017) and in New Zealand with 2341
registered cases in 2010 (HPA andMelNetNZ 2014). For 2014 in
the USA, the predicted incidence was 73,870 per annum and the
predicted number of deaths was 9940 (Siegel 2015). The highest
rates in Europe are seen in north-western Europe and the Scan-
dinavian countries, with a highest incidence reported in Switzer-
land: 25.8 per 100,000 in 2012. Rates in England have tripled
from 4.6 and 6.0 per 100,000 in men and women, respectively, in
1990, to 18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012). In-
deed, in the UK, melanoma has one of the fastest rising incidence
rates of any cancer and has had the biggest projected increase in
incidence between 2007 and 2030 (Mistry 2011). In the decade
leading up to 2013, age standardised incidence increased by 46%,
with 14,500 new cases in 2013 and 2459 deaths in 2014 (Cancer
Research UK 2017b). Rates are higher in women than in men;
however, the rate of incidence in males is increasing faster than in
females (Arnold 2014).
The rising incidence in melanoma is thought to be primarily re-
lated to an increase in recreational sun exposure, tanning bed use
and an increasingly ageing population with higher lifetime recre-
ational ultraviolet (UV) exposure, in conjunction with possible
earlier detection (Linos 2009; Belbasis 2016). Putative risk fac-
tors are reviewed in detail elsewhere (Belbasis 2016); however, risk
factors can be broadly divided into host or environmental fac-
tors. Host factors include pale skin and light hair or eye colour;
older age (Geller 2002); male sex (Geller 2002); previous skin
cancer (Tucker 1985); genetically inherited skin disorders, for ex-
ample xeroderma pigmentosum (Lehmann 2011); a family his-
tory of melanoma (Gandini 2005a); and predisposing skin lesions,
such as high melanocytic naevus counts (Gandini 2005a), clin-
ically atypical naevi (Gandini 2005a), or large congenital naevi
(Swerdlow 1995). Environmental factors include recreational, oc-
cupational, and work-related exposure to sunlight (both cumu-
lative and episodic burning) (Gandini 2005b; Armstrong 2017);
artificial tanning (Boniol 2012); and immunosuppression, such as
that seen in organ transplant recipients or HIV-positive individ-
uals (DePry 2011). Lower socioeconomic class may be associated
with delayed presentation and thus more advanced disease at di-
agnosis (Reyes-Ortiz 2006).
Five-year survival for stage I melanoma is reported to be 91% to
95%, falling to 27% to 69% in stage III disease (Balch 2009). Tu-
mour thickness, the presence of tumour ulceration and age are the
main determinants of melanoma prognosis, and prognostic tools
have been developed that include such features (Mahar 2016).
Before the advent of targeted and immunotherapies, metastatic
melanoma (involving distant sites and visceral organs) resulted
in median survival of six to nine months with a three-year sur-
vival of 15% (Balch 2009; Korn 2008). Despite rising incidence,
melanoma mortality appears to be stable (Apalla 2017). Between
1975 and 2010, five-year relative survival for melanoma in the
US increased from 80% to 94% but mortality rates showed little
change, at 2.1 per 100,000 deaths in 1975 and 2.7 per 100,000 in
2010 (Cho 2014). Increasing incidence in localised disease over
the same period (from 5.7 to 21 per 100,000) suggests that the ob-
served survival benefits may be due to earlier detection and height-
ened vigilance (Cho 2014); however, targeted therapies for stage
IV melanoma (e.g. BRAF inhibitors) have improved survival ex-
pectation, and immunotherapies are demonstrating potential for
long-term survival (Pasquali 2018).
Treatment of melanoma
For primary melanoma, the mainstay of definitive treatment is
wide local excision of the lesion, to remove both the tumour and
any malignant cells that might have spread into the surrounding
skin (Sladden 2009; Marsden 2010; NICE 2015; Garbe 2016;
SIGN 2017). Recommended surgical margins vary according to
tumour thickness, as described in Garbe 2016, and stage of disease
at presentation, as in NICE 2015 guidelines. The role of narrower
(e.g. 1 cm healthy tissue) excision margins for thinner lesions is
still debated (Sladden 2009; Wheatley 2016). Following histolog-
ical confirmation of diagnosis, the lesion is staged according to the
American Joint Committee on Cancer (AJCC) Staging System to
guide treatment (Balch 2009). Stage 0 refers to melanoma in situ;
stages I to II, localised melanoma; stage III, regional metastasis;
and stage IV, distant metastasis (Balch 2009). The main prognos-
tic indicators can be divided into histological and clinical factors.
Histologically, Breslow thickness is the single most important pre-
dictor of survival, as it is a quantitativemeasure of tumour invasion
that correlates with the propensity for metastatic spread (Balch
2001).Microscopic ulceration,mitotic rate,microscopic satellites,
regression, lymphovascular invasion, and nodular (rapidly grow-
ing) or amelanotic (lacking in melanin pigment) subtypes are also
associated with worse prognosis (Shaikh 2012; Moreau 2013).
Independent of tumour thickness, prognosis is worse in older peo-
ple (Geller 2002); males (Geller 2002); those with recurrent le-
sions (Dong 2000); and in those with distant lymph node involve-
ment (microscopic or macroscopic), metastatic disease, or both,
at the time of primary presentation (Balch 2009). There is debate
regarding the prognostic effect fromprimary lesion site, with some
evidence suggesting a worse prognosis for truncal lesions or those
on the scalp or neck (Zemelman 2014).
Index test(s)
Smartphones are rapidly evolving from communication and en-
tertainment devices to tools with specialised applications (’apps’)
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that are intimately involved inmany aspects of daily life (Kassianos
2015). The processing powers of modern smartphones allow their
use in more demanding tasks such as image analysis (Massone
2007). Melanoma risk assessment tools are recent additions and
include applications such as Mel App and Skin Scan (Robson
2012).
Once downloaded to a user’s mobile phone (both Android and
Apple iOS platforms), the applications can act as an information
resource about melanoma or other skin cancer, provide guidance
on whether people should seek medical advice for a particular
lesion that they have photographed with the mobile phone, or be
used to monitor skin lesions to identify any changes over time
(Kassianos 2015).
Some applications that provide guidance on particular skin le-
sions can use internally programmed algorithms (or ’artificial in-
telligence’) to catalogue and classify the lesion images. Others are
store-and-forward applications that forward the photograph of the
lesion to an experienced professional such as a dermatologist for
review and then communicate a recommendation regarding the
nature of the lesion to the user (essentially allowingmembers of the
public direct access to a teledermatology-type service) (Kassianos
2015).
The artificial intelligence-based applications use algorithms to
compare the acquired image against a bank of exemplar images
of malignant and benign lesions or compare the image against a
host of benign and malignant lesion characteristics learned from
analysing thousands of other images to assess the likelihood of
melanoma. These algorithms are generally based on fractal anal-
ysis. A fractal, in biology, is a natural phenomenon that exhibits
a repeating pattern at every scale (Landini 2011). Fractal analysis
can provide a quantitative measure of irregularity where regularity
is expected. With regard to melanoma, this includes irregularities
in a lesion’s physical characteristics, such as those used in estab-
lished algorithms to assist in the diagnosis of melanoma (e.g. the
’ABCs’ of melanoma (Friedman 1985)), as well as texture, pat-
terns, and other geometric features. Fractal analysis has been used
for diagnosis of other cancers, for example, mammography for
breast cancer (Rangayyan 2007; Raguso 2010), but it has not his-
torically been made available to consumers for assessment of their
own malignancy risk. A major benefit of fractal analysis is that it
is automated and thus observer-independent.
A recent review by Kassianos 2015 identified 39 available smart-
phone applications related to melanoma; most were multifunc-
tional in that they provided information about melanoma in addi-
tion to lesion classification or ameans ofmonitoring a given lesion.
Just under half of the applications (46%; 18/39) provided some
form of image analysis, and a quarter (23%; 9/39) used ’store-and-
forward’ lesion image review by a dermatologist. Those providing
image analysis often did not describe how the photographic images
were processed and analysed to provide advice on the likelihood
of melanoma (Kassianos 2015). Authors described four applica-
tions as providing an assessment of the likelihood of melanoma:
two used an artificial intelligence-based algorithm based on the
ABCDE method (assessing asymmetry, borders, colour, diameter
and evolution), one provided a risk approximation based on the
completion of a visual analogue scale by the application user,
and one provided insufficient information regarding the method
involved (Kassianos 2015). Between 2014 and 2018, 235 new
dermatology smartphone applications became available (an in-
crease of 80.8%), including dozens of teledermatology applica-
tions, which rose from 32 to 106 (Flaten 2018).
Clinical pathway
Individuals or their relatives are often best placed to recognise sus-
picious or changing skin lesions and may use a range of resources
to become better informed about their concerns. Smartphone ap-
plications could have a role very early on in the clinical pathway,
as they are readily accessible and potentially offer an instant risk
assessment of the likelihood of malignancy, reassuring those with
benign appearing lesions and effectively triaging those who need
to seek furthermedical attention from a clinician formore detailed
assessment of the lesion (Figure 2).
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Figure 2. Example pathway for an individual using a smartphone application to examine a suspicious mole
in resource settings with smartphones
In the UK, people with concerns about a new or changing lesion
(either based on skin self-examination alone or with the aid of a
mobile phone application) will then present to their general prac-
titioner (GP) rather than directly to a specialist in secondary care
(Figure 3). If the GP has concerns, they may refer the patient to a
specialist in secondary care - usually a dermatologist but sometimes
a plastic surgeon or an ophthalmologist. Other systems may be in
place in other countries, with the possibility of presenting directly
to a skin specialist. Other specialists may also identify suspicious
skin lesions, for example, a general surgeon or other specialist sur-
geon (including ear, nose, and throat (ENT) specialist (Figure 3)
and refer patients to a specialist consultation with a dermatologist
or plastic surgeon. Current UK guidelines recommend that GPs
assess all suspicious pigmented lesions presenting in primary care
by taking a clinical history and visually inspecting them using the
revised seven-point checklist (MacKie 1990); GPs should urgently
refer suspicious pigmented skin lesions for specialist assessment
within two weeks (Marsden 2010; Chao 2013; NICE 2015). Evi-
dence is emerging, however, to suggest that excision of melanoma
by GPs is not associated with increased risk compared with out-
comes in secondary care (Murchie 2017). The specialist clinician
will use history-taking, visual inspection of the lesion (in compar-
ison with other lesions on the skin), and usually dermoscopy to
inform a clinical decision. If clinicians suspect melanoma, then ur-
gent excision is advised. Other lesions such as suspected dysplastic
naevi or pre-malignant lesions such as lentigo maligna may also be
referred for a diagnostic biopsy, further surveillance, or reassurance
and discharge.
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Figure 3. Current clinical pathway for people with skin lesions.
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Role of index test(s)
Advances in smartphone technology have provided innovative
platforms, where people can become more educated about their
medical conditions, leading to better engagement with healthcare
professionals (Robertson 2014). The use of smartphone technol-
ogy can facilitate active self-management health practices and pro-
vide patients information related to their condition (Tyagi 2012).
As they are self-initiated, psychological barriers to seeking medical
advice can diminish, as assessments take place outside clinical set-
tings and are often interactive and personalised (Tyagi 2012). The
advances in smartphone technology provide new strategies for en-
gaging patients in the management of potentially suspicious skin
lesions, increasing the likelihood of detecting melanoma earlier
in the progression of the disease. Early detection of melanoma is
crucial for patients, dramatically improving survival and reducing
morbidity (Balch 2009). There is increased value to the users and
healthcare professionals alike, as more educated patients can bet-
ter engage with their doctors, making consultations more effective
and efficient (Robertson 2014).
The greatest concern about mobile phone applications in this con-
text relates to their ability to accurately stratify lesions by level of
risk of development of melanoma, particularly given the potential
for falsely reassuring people that their lesion is benign. There is real
concern that people could be dissuaded from accessing healthcare
advice if the app deems their lesion to be low risk (Robson 2012).
The most useful applications will therefore be those that max-
imise sensitivity over specificity for the detection of melanoma.
Howeve, this feeds a concern that those who use such applications
may be the ’worried well’ rather than those who might actually
have melanoma, which could flood limited healthcare resources
with unnecessary referrals or simply generate profits for private
providers who may take advantage of public cancer anxiety.
Alternative test(s)
For the purposes of our series of reviews, we consider each com-
ponent of the diagnostic process, including visual inspection or
clinical examination (whether delivered in-person or remotely via
teledermatology), as a diagnostic or index test, the accuracy of
which can be established in comparison with a reference standard
of diagnosis, either alone or in combination with other available
technologies.
Once an individual or their relatives have identified a suspicious
lesion, the only alternative to the use of a mobile phone applica-
tion is to immediately seek medical advice from their GP or spe-
cialist clinician. The clinician will then use history-taking, visual
inspection of the lesion (in comparison with other lesions on the
skin), and usually dermoscopy to inform a clinical decision (Figure
2). Our series of systematic reviews has also assessed the accuracy
of visual inspection alone and dermoscopy plus visual inspection
(Dinnes 2018a; Dinnes 2018b).
Chuchu 2018 has also conducted a review of the accuracy of tele-
dermatology, whereby dermatologists receive clinical photographs
or dermoscopic images of a skin lesion, traditionally from non-
specialist clinicians, and give a specialist opinion on a suspicious
lesion. This can be done on a store-and-forward basis, using digital
cameras or mobile phones to acquire photographs or dermoscopic
images of a lesion, or via a live video link. According to UK guide-
lines, ’full dermatology’ services (i.e. a replacement for a face-to-
face consultation) require both clinical and dermoscopic images,
whereas ’triage teledermatology’ services process only dermoscopic
images where facilities permit (BAD 2013).
Teledermatology not only allows clinicians rapid access to expert
opinion but may lead to a reduction in waiting times and limit
unnecessary referrals (Ndegwa 2010; Warshaw 2010; Bashshur
2015). In rural areas, where people’s access to speciality services
can have significant and potentially off-putting travel and time
implications, teledermatology has the potential to increase access
to specialist opinion.
Teledermatology is also becoming available in a community set-
ting, especially within community or ’high street’ pharmacies (for
example, the Boots ’Mole Scanning Service’, www.boots.com/
health-pharmacy-advice/skin-services/mole-
scanning-service), and is therefore a potential alternative to smart-
phone applications. Due to their extended opening hours, ease of
access, presence of healthcare professionals and availability of con-
sultation rooms, community pharmacies are increasingly provid-
ing early detection services (Kjome 2016), such as mole scanning
by trained pharmacy staff. In theory, using pharmacies as the first-
line identifier to separate those with skin lesions requiring follow-
up from those who do not, gives general practitioners and special-
ists more time and resources for those who require intervention
(Kjome 2016).
A number of other tests that may have a role in the diagnosis
of melanoma in a specialist setting have been reviewed as part
of our series of systematic reviews, including reflectance confo-
cal microscopy, optical coherence tomography, computer-assisted
diagnosis or artificial intelligence-based techniques, and high-fre-
quency ultrasound (Dinnes 2018c; Ferrante di Ruffano 2018a;
Ferrante di Ruffano 2018b; Dinnes 2018d).
Evidence permitting, we will compare the accuracy of available
tests in anoverviewof review, exploitingwithin-study comparisons
of tests and allowing the analysis and comparison of commonly
used diagnostic strategies where tests may be used alone or in
combination.
Rationale
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Our series of reviews of diagnostic tests used to assist clinical diag-
nosis of melanoma aims to identify the most accurate approaches
to diagnosis and provide clinical and policy decision-makers with
the highest possible standard of evidence on which to base deci-
sions. With increasing rates of melanoma incidence and the push
towards the use of dermoscopy and other high-resolution image
analysis in primary care without adequate evidence of effective-
ness or safety, the anxiety around missing early cases needs to be
balanced against the risk of over referrals, to avoid sending too
many people with benign lesions for a specialist opinion. It is ques-
tionable whether all skin cancers picked up by sophisticated tech-
niques, even in specialist settings, help to reduce morbidity and
mortality or whether newer technologies run the risk of increasing
false positive results. It is also possible that use of some technologies
(e.g. widespread use of dermoscopy in primary care with no train-
ing), could actually result in harm by missing melanomas if they
are used as replacement technologies for traditional history-tak-
ing and clinical examination of the entire skin; many branches of
medicine have noted the danger of such ’gizmo idolatry’ amongst
doctors (Leff 2008).
Smartphone applications in general are already widely available
and used by consumers, and the popularity of such platforms to
offer clinical and diagnostic advice is steadily increasing. Given
the rapidly changing evidence base and lack of available systematic
reviews on the topic, there is a need for an up-to-date analysis of
the accuracy of smartphone applications.
As several reviews for each topic area followed the same methodol-
ogy, we prepared generic protocols in order to avoid duplication of
effort: one for diagnosis of melanoma, Dinnes 2015a, and one for
diagnosis of keratinocyte skin cancers, Dinnes 2015b. The Back-
ground and Methods sections of this review therefore use some
text that was originally published in the protocol concerning the
evaluation of tests for the diagnosis of melanoma (Dinnes 2015a)
and some text that overlaps some of our other reviews (Dinnes
2018b).
O B J E C T I V E S
To assess the diagnostic accuracy of smartphone applications to
rule out cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants in adults with concerns about suspicious skin
lesions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the
result of the index test with that of a reference standard, including
the following.
• Studies where all participants receive a single index test and
a reference standard.
• Studies where all participants receive more than one index
test(s) and reference standard.
• Studies where participants are allocated (by any method) to
receive different index tests or combinations of index tests, and
all receive a reference standard (between-person comparative
studies (BPC)).
• Studies that recruit series of participants unselected by true
disease status (referred to as case series for the purposes of this
review).
• Diagnostic case-control studies that separately recruit
diseased and non-diseased groups (see Rutjes 2005).
• Both prospective and retrospective studies.
• Studies where previously acquired clinical or dermoscopic
images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2 × 2 con-
tingency data or small studies with fewer than five disease-posi-
tive or disease-negative participants. Although the size threshold
of five is arbitrary, such small studies are likely to give unreliable
estimates of sensitivity or specificity and may be biased, like small
randomised controlled trials of treatment effects.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with pigmented skin lesions or le-
sions suspicious for melanoma. These could include those at high
risk of developingmelanoma, including those with a family history
or previous history of melanoma skin cancer, atypical or dysplas-
tic naevus syndrome, or genetic cancer syndromes. Ideally, par-
ticipants should be recruited from community settings; however,
due to an anticipated paucity of data, we considered participants
recruited from any setting as eligible. We excluded studies that
recruited only participants with malignant diagnoses and studies
that compared test results in participants with malignancy com-
pared with test results based on ’normal’ skin as controls, due to
the bias inherent in such comparisons (Rutjes 2006).We excluded
studies with more than 50% of participants aged 16 and under.
Index tests
We included studies evaluating smartphone applications intended
for use by any individual (or member of the public) with a smart-
phone in a community setting who has a skin lesion that concerns
them. Applications intended for use by smartphone users were
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considered to be those using standard photographs acquired by
the mobile phone. We considered applications to be intended for
clinician use (e.g. GPs) as a way to access specialist dermatologist
opinion (i.e. for store-and-forward teledermatology assessments)
when the applications required dermoscopic or other microscopic
attachments for the acquisition of magnified images.
We included studies developing new mobile phone applications
(i.e. derivation studies) if they used a separate independent ’test
set’ of participants or images to evaluate the new approach.
We excluded studies if they:
• used a statistical model to produce a data-driven equation
or algorithm based on multiple diagnostic features, with no
separate test set;
• used cross-validation approaches such as ’leave-one-out’
cross-validation (Efron 1983); or
• evaluated the accuracy of the presence or absence of
individual lesion characteristics or morphological features, with
no overall diagnosis of malignancy.
Target conditions
The target condition was cutaneous melanoma and atypical in-
traepidermalmelanocytic variants (i.e. includingmelanoma in situ
or lentigo maligna, which has a risk of progression to invasive
melanoma).
Reference standards
The preferred reference standard for establishing the final diag-
nosis of a skin lesion is histopathological diagnosis of the excised
lesion or biopsy sample in all eligible lesions. Histopathlogical as-
sessment is not a perfect reference standard because it only sam-
ples lesions for examination and may therefore miss tumour cells
in non-sampled portions. As it is a subjective assessment, there is
also some degree of inter-observer variation, especially for border-
line lesions. A qualified pathologist or dermatopathologist should
perform histopathology. Ideally, reporting should be standardised,
detailing a minimum dataset including the histopathological fea-
tures of melanoma needed to determine staging according to the
American Joint Committee on Cancer (AJCC) Staging System
(e.g. Slater 2014). We did not apply the reporting standard as a
necessary inclusion criterion but extracted any pertinent informa-
tion.
Due to the potential for partial verification (with lesion excision or
biopsy unlikely to be carried out for all benign-appearing lesions
within a representative population sample), we also accepted clin-
ical follow-up of benign-appearing lesions, cancer registry follow-
up and ’expert opinion’ with no histology or clinical follow-up as
eligible reference standards. We considered the risk of differential
verification bias (as misclassification rates of histopathology and
follow-up will differ) in our quality assessment of studies.
We considered all of the above reference standards for establishing
final diagnoses of the lesion, with the following caveats:
• all study participants with a final diagnosis of the target
disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical
follow-up; and
• at least 50% of all participants with benign lesions must
have either a histological diagnosis or clinical follow-up to
confirm benignity.
The ability of a smartphone application to correctly triage those
who need further assessment of suspicious skin lesions is not the
only outcome of interest for this type of test, however. It is possible
to estimate referral accuracy (or ability of the smartphone applica-
tion to approximate an in-person lesion assessment) by comparing
the action recommended by the smartphone application with the
management recommendation from face-to-face assessment by an
appropriately qualified clinician. To this end, ’expert opinion’ as
the sole reference standard is an eligible reference standard for our
reviews of both mobile phone applications and for teledermatol-
ogy.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 3). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed on MEDLINE. The Information Special-
ist devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies.
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• MEDLINE via OVID (from 1946);
• MEDLINE In-Process & Other Non-Indexed Citations via
OVID; and
• Embase via OVID (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies.
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 7), in the Cochrane Library.
• The Cochrane Database of Systematic Reviews (CDSR;
2016, Issue 8), in the Cochrane Library.
• Cochrane Database of Abstracts of Reviews of Effects
(DARE; 2015, Issue 2).
• CRD HTA (Health Technology Assessment) database
(2016; Issue 3).
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We have screened relevant systematic reviews identified by the
searches for their included primary studies, and we included any
missed by our searches. We have checked the reference lists of
all included papers, and subject experts within the author team
reviewed the final list of included studies. We did not perform
electronic citation searching.
Data collection and analysis
Selection of studies
At least one author (JDi or NC) screened titles and abstracts, dis-
cussing and resolving any queries by consensus. A pilot screen of
539 MEDLINE references showed good agreement (89% with a
kappa of 0.77) between screeners. At initial screening, we included
primary test accuracy studies and test accuracy reviews (for scan-
ning of reference lists) of any test used to investigate suspected
melanoma, basal cell carcinoma (BCC), or cutaneous squamous
cell carcinoma (cSCC). Both a clinical reviewer (from a team of
12 clinician reviewers) and a methodologist reviewer (JDi or NC)
applied inclusion criteria (Appendix 4) to all full text articles, re-
solving disagreements by consensus or by consultation with a third
party (JDe, CD, HW or RM). We contacted authors of eligible
studies when they presented insufficient data to allow for the con-
struction of 2 × 2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodological reviewer
(JDi,NCor LFR) independently extracted data concerning details
of the study design, participants, index test(s) or test combinations
and criteria for index test positivity, reference standards, and data
required to populate a 2 × 2 diagnostic contingency table for each
index test using a piloted data extraction form.Datawere extracted
at all available index test thresholds.We resolved disagreements by
consensus or in consultation with a third party (JDe, CD, HW or
RM).
We contacted authors of included studies where there was missing
information related to the target condition (in particular to allow
the differentiation of invasive cancers from in situ variants) or di-
agnostic threshold. We contacted authors of conference abstracts
published from 2013 to 2015 to ask whether full data were avail-
able, marking them as ’pending’ when we could not obtain a full
paper. We will revisit these in future review updates.
Where we identified multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If contact with authors was unsuccessful, we used the
most complete and up-to-date data source where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the topic
of skin cancer diagnosis (see Appendix 5). We piloted the mod-
ified QUADAS-2 tool on five full-text articles. One clinical and
one methodological reviewer (JDi, NC or LFR) independently
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assessed quality for the remaining studies, resolving any disagree-
ment by consensus or in consultation with a third party where
necessary (JDe, CD, HW or RM).
Statistical analysis and data synthesis
Due to scarcity of data and the poor quality of studies, we did not
undertake a meta-analysis for this review. For illustrative purposes,
we plotted estimates of sensitivity and specificity on coupled forest
plots for each applicationunder consideration.Our unit of analysis
was the lesion rather than the patient, as initial treatment in skin
cancer is directed to the lesion and not systemically to a patient
(thus it is important to be able to correctly identify cancerous
lesions within each patient). Moreover, this is the most common
way in which the primary studies reported data. Although there is
a theoretical possibility of correlations of test errors whenmultiple
lesions are included from the same patients, most studies include
very few patients with multiple lesions, and any potential impact
on findings is likely to be very small, particularly in comparison
with other concerns regarding risk of bias and applicability. For
each analysis, we included only one dataset per study to avoid
multiple counting of lesions.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting
the forest plots of sensitivity and specificity and summary receiver
operating characteristics (ROC) plots. we did not identify enough
studies to allow meta-regression to investigate potential sources of
heterogeneity.
Sensitivity analyses
We did not perform any sensitivity analyses.
Assessment of reporting bias
Due to uncertainty about the determinants of publication bias for
diagnostic accuracy studies and the inadequacy of tests for detect-
ing funnel plot asymmetry (Deeks 2005), we did not perform any
tests to detect publication bias.
R E S U L T S
Results of the search
We screened a total of 34,517 unique references for inclusion. Of
these, we reviewed1051 full-text papers for eligibility and included
203 publications in at least one of the suite of reviews of tests to
assist in the diagnosis of melanoma or keratinocyte skin cancer.
Figure 4 provides a PRISMA flow diagram of search and eligibil-
ity results. We considered 16 studies to be potentially eligible for
this review of smartphone applications and ultimately included
two publications. Figure 4 lists the reasons for exclusion, while the
Characteristics of excluded studies tables list both the studies and
the reasons we excluded them. Two studies included fewer than
five melanoma cases (Massone 2007; Robson 2012); three studies
used an inappropriate index test (including two studies where mo-
bile phones were used to capture dermoscopic (Massone 2007) or
otherwise magnified (Diniz 2016) images in a specialist clinic set-
ting); two studies were derivation studies that did not separate data
for training and test sets (Ramlakhan 2011;Wadhawan 2011), and
one study was a duplicate or related publication (Von Braunmühl
2015 reported data for the same patients as Maier 2015). A list of
all studies excluded from the full series of reviews is available as a
supplementary file (please contact skin.cochrane.org for a copy).
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Figure 4. PRISMA flow diagram.
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Across all of our reviews, we contacted the corresponding authors
of 84 studies to ask them to supply further information needed to
allow study inclusion (37 studies), to clarify diagnostic thresholds
(18 studies) or to define the target condition (29 studies). We
received responses from 39 authors, allowing the inclusion of 4
studies across various reviews (and 1 study for this review, Wolf
2013), and providing data clarifications for 23 others.
This review reports on two cohorts of lesions published in two
studies that provide six datasets (Wolf 2013; Maier 2015). The
applications successfully analysed a total of 332 lesions, including
86 melanomas. The studies did not report the number of partici-
pants with lesions included in the studies.
Wolf 2013 retrospectively evaluated photographs of lesions se-
lected from their dermatology database of lesions that had been
scheduled for excision using a case-control type design. Health
professionals routinely captured these lesion images from partici-
pants who had presented with suspicious skin lesions in a derma-
tological setting rather than the community setting where these
applications are intended to be used, and the study included only
lesions with a final diagnosis of melanoma, melanoma in situ,
lentigo, benign naevi (including compound, junctional and low
grade dysplastic naevi), dermatofibroma, sebhorrhoeic keratosis
and haemangioma. The study included lesions with good quality
photographs (as assessed by one or two dermatologists) and with a
clear histological diagnosis. The study excluded lesions that were
uncommon or had an equivocal diagnosis (such as ’melanoma can-
not be ruled out’ or ’atypicalmelanocytic proliferation’) and lesions
with moderate or high grade atypia. Investigators excluded more
than half the images reviewed for inclusion in the study (52%;
202/390) due to poor image quality, the presence of identifiable
patient features or insufficient clinical or histological information.
The applications analysed 3 to 29 additional lesions, but trialists
considered these to be unevaluable or test failures (see Findings).
Maier 2015 conducted a prospective case series of patients with
melanocytic skin lesions seen routinely at the department of der-
matology for skin cancer screening. It is unclear whether partici-
pants were referred or could access the dermatology clinic directly.
Up to three smartphone images (photographs) per lesion were
taken, presumably by the dermatologist, before excising the lesion;
however, authors did not clearly describe the image acquisition
process. The study excluded 20/195 lesions (10%) due to poor
image quality or incomplete imaging. Study authors excluded an
additional 31 lesions they considered as test failures for the pur-
poses of this review (see Findings), including 13 due to “two-point
differences” (explained as non-consecutive risk classes, presumably
for different images of the same lesion) and 18 “tie-cases” (de-
fined as having an equal number of results in two consecutive risk
classes, e.g. 1 high risk, 1 medium risk and 1 low risk result).
Wolf 2013 took place in the USA and Maier 2015 in Germany.
Neither study reported information on the number of patients
recruited or their characteristics (e.g. age and sex); total numbers
of included lesions were 188 in Wolf 2013 and 144 in Maier
2015. Both studies reported on the accuracy of smartphone ap-
plications for detecting melanoma and its atypical intraepidermal
melanocytic variants. The prevalence of melanoma was 18% in
Maier 2015 and 35% in Wolf 2013.
Wolf 2013 evaluated four different smartphone applications, pro-
viding no names to avoid consumer bias; they numbered the ap-
plications one to four to allow an assessment of accuracy. Three
applications were artificial intelligence-based classifications of le-
sions as ’problematic’ versus ’okay’ (App 1), ’melanoma’ versus ’not
melanoma’ (App 2) and ’high risk’ versus ’medium/low-risk’ (App
3) as part of the assessment of the images. It was also possible to
dichotomise data for App 3 as ’high/medium risk’ (test positive)
versus ’low risk’ (test negative). App 4 used a store-and-forward
approach with remote lesion assessment by a qualified dermatol-
ogist. Users could run this application on either a smartphone or
a website, with lesion images uploaded and transmitted remotely
to a dermatologist to make an assessment and return it to the user
within 24 hours. The output given was ’atypical’ versus ’typical’.
Maier 2015 evaluated an automated risk assessment algorithm us-
ing the SkinVision App; this relied on fractal image analysis of
three images per lesion. The application classified lesions as ’high
risk’ versus ’medium or low risk’. The study also reported the di-
agnostic accuracy of face-to-face clinical diagnosis by a dermatol-
ogist for the same lesions.
In both studies the reference standard diagnosis was made by his-
tology alone (all lesions were either biopsied or excised).
Methodological quality of included studies
Figure 5 and Figure 6 summarise the overall methodological qual-
ity of included studies.
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
Figure 6. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
We assessed both studies as being at high risk of bias for participant
selection due to the inappropriate exclusion of lesions that would
have otherwise been eligible for assessment with the applications.
Wolf 2013 also used a case-control design, including only lesions
with particular final diagnoses. Similarly, both studies caused high
concern regarding included participants and setting, due to un-
clear reporting of patient samples and whether they included mul-
tiple lesions per patient. Wolf 2013 excluded lesions that were
common or with equivocal diagnoses. All studies included only
lesions selected for excision. This is not a representative spectrum
of lesions that would be observed in daily life but rather a highly
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selected sample of participants. These participants would have al-
ready presented to a doctor with concerns about a particular le-
sion and therefore are likely represent a more severe spectrum of
abnormality, which will artificially increase the sensitivity of the
test in comparison to use by smartphone users in general.
We assessed both studies as being at low risk of bias in the in-
dex test domain, with the artificial intelligence-based assessment
made without knowledge of the histological diagnosis. All had a
pre-specified threshold. However, both studies caused high con-
cern about applicability of the index tests, which were not used
as intended in practice. Wolf 2013 used archived photographs of
lesions rather than images taken using a phone and did not report
the real names of the applications used. Maier 2015 did use smart-
phone images; however, the details around the imaging process
were unclear.
All studies reported the use of an acceptable reference standard;
however, Maier 2015 did not report blinding of histology to the
index test result. Only Wolf 2013 reported histopathological in-
terpretation by an experienced dermatopathologist.
Both studies were at high risk of bias for flow and timing due to
exclusion of unevaluable images from further analysis (authors do
state the numbers excluded, allowing computation of test failure
rates). Both were unclear on the interval between image capture
and performance of the reference standard.
Findings
Detection of invasive melanoma or atypical
intraepidermal melanocytic variants
Across the five different applications that the two studies assessed,
sensitivities for the detection of invasive melanoma or atypical in-
traepidermal melanocytic variants ranged from 7% (95% confi-
dence interval (CI) 2% to 16%) to 98% (95% CI 90% to 100%)
and specificities from 30% (95% CI 22% to 40%) to 94% (95%
CI 87% to 97%; Figure 7).
Figure 7. Forest plot of tests: showing sensitivity and specificity of all the applications for the detection of cutaneous
melanoma and atypical intraepidermal variants 1 App 1[problematic vs okay], 2 App 2 [mel vs not mel], 3 App 3(a)
[high risk vs medium+low risk], 4 App 3(b) [high+medium risk vs low risk], 5 App 4 (remote diagnosis)
[atypical vs typical], 6 SkinVision [high risk vs medium/low risk].
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One of the four artificial intelligence-based applications attempted
to correctly identify lesions as melanomas or not. For App 2 in
Wolf 2013 (185 lesions and 58 melanoma cases), the resulting
sensitivity was 69% (95% CI 55% to 80%), and specificity was
37% (95% CI 29% to 46%).
The remaining three artificial intelligence-based algorithms at-
tempted to categorise lesions as high risk or ’problematic’ or not
(Figure 7). Sensitivities were around 70% for App 1 in Wolf 2013
(70%, 95% CI 57% to 81%) and for the SkinVision app inMaier
2015 (73%, 95% CI 52% to 88%) but only 7% (95% CI 2%
to 16%) for App 3 in Wolf 2013. The corresponding specificities
for the three applications were 39% (95% CI 31% to 49%; Wolf
2013; 182 lesions and 60 melanomas), 83% (95% CI 75% to
89%;Maier 2015; 144 lesions and26melanomas), and94% (95%
CI 87% to 97%;Wolf 2013; 170 lesions and 59 melanomas). De-
creasing the threshold for considering lesions as test positive (i.e.
including both high and medium risk lesions) for App 3 in Wolf
2013 (denoted App 3b in Figure 7) increased sensitivity from 7%
to 54% (95% CI 41% to 67%), with a fall in specificity from 94%
to 61% (95% CI 52% to 70%).
The final application, App 4 in Wolf 2013, was a store-and-for-
ward system, with a dermatologist classifying lesion images as atyp-
ical or typical. The sensitivity for this application was 98% (95%
CI 90% to 100%) and specificity 30% (95% CI 22% to 40%;
159 lesions and 54 melanoma cases).
This application however, recorded the highest percentage of ’test
failures’ in the Wolf 2013 study (i.e. eligible lesions analysed by
the applications but recorded as unevaluable). The test failure rates
were: 3% (App 1), 2% (App 2), 6% (App 3) and 15% (App 4;
designated by the dermatologist as ’send another photograph’ or
’unable to categorise’) (Table 1). Three of the four applications
classed at least one melanoma as unevaluable, with the dermatol-
ogist conducting the assessment for the store-and-forward appli-
cation (App 4) missing 6 (10%) melanomas for this reason.
The SkinVision application described in Maier 2015 analysed a
total of 31 lesions (18%; 31/175) as unevaluable (Table 1). Al-
though the studies did not report the number ofmelanomas classed
as unevaluable; however, the study authors excluded 35% of all
melanomas originally eligible for the study (14/40) due to poor
image quality or because the images were classed as unevaluable.
Maier 2015 also reported the accuracy of face-to-face clinical di-
agnosis of the same lesions by a dermatologist. These data are not
directly comparable to those that the application generated, as the
in-person assessment relates to the diagnosis of melanoma whereas
the SkinVision application was developed to identify lesions at
high risk of melanoma. The sensitivity of the face-to-face assess-
ment was 85% (95% CI 65% to 96%) and specificity, 97% (95%
CI 93% to 99%; Figure 8; 144 lesions and 26 melanomas).
Figure 8. Forest plot of tests: SkinVision automated diagnosis compared to face to face clinical diagnosis by a
dermatologist 6 SkinVision [high risk vs medium/low risk], 7 Face-to-face clinical diagnosis [high risk vs
medium/low risk].
Investigations of heterogeneity
Wewere unable to undertake investigations of heterogeneity listed
in the protocol due to an insufficient number of studies.
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D I S C U S S I O N
Summary of main results
This review aimed to assess the accuracy of smartphone applica-
tions for detecting invasive melanoma or atypical intraepidermal
melanocytic variants. We included two studies with a total of 332
lesions, 86 of which were melanomas (Summary of findings).
Studies were generally of poor methodological quality. Risk of bias
was low for both studies only for the index test domain. Poor re-
porting did not always allow adequate judgement of the quality of
the reference standard. Study participants were highly selected in
comparison to those whomight choose to use a smartphone appli-
cation to check a skin lesion that was causing them concern. Both
of the studies used photographs of skin lesions that were scheduled
for excision in a dermatology clinic setting, and clinicians were
the ones who took the photographs instead of people using their
own smartphones, potentially leading to the acquisition of higher
quality images. Studies were blinded for index test interpretation
and used pre-specified test thresholds and adequate reference stan-
dards. One study did not report blinding of the reference standard
to the lesion images, and one did not mention interpretation by
an experienced histopathologist. We are therefore unable to make
a reliable estimate of the accuracy of smartphone applications for
detecting melanoma or intra-epidermal melanocytic variants.
Across the four artificial intelligence-based applications that classi-
fied lesion images (photographs) as melanomas (one application)
or as high risk or ’problematic’ lesions (three applications), sensi-
tivities ranged from 7% (95% CI 2% to 16%) to 73% (95% CI
52% to 88%) and specificities from 37% (95% CI 29% to 46%)
to 94% (95%CI 87% to 97%). Thismeans that between 27%and
93% of invasive melanoma or atypical intraepidermal melanocytic
variants were not picked up as requiring further assessment by a
clinician by the automated applications (or as melanomas by one
of the four applications). With a prevalence of melanoma rang-
ing between 18% and 37% for these evaluations, the number of
melanomas missed was between 7 and 55.
The single application using store-and-forward review of lesion
images by a dermatologist had a sensitivity of 98% (95% CI 90%
to100%) and specificity of 30% (95% CI 22% to 40%); the der-
matologist missed one melanoma.
The number of test failures (lesion images that the applications
analysed but that the study authors classed as unevaluable and
excluded) ranged from 3 to 31 (or 2% to 18% of lesions analysed).
The store-and-forward application had one of the highest rates
of test failure (15%). Three of the four applications classed at
least one melanoma as unevaluable, with the highest number of
excluded melanomas (6/60 melanomas assessed) resulting from
dermatologist evaluation of the store-and-forward images.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and methodol-
ogists, and contact with authors to allow study inclusion or clarify
data. We planned a clear analysis structure to allow estimation of
test accuracy in different study populations and undertook a de-
tailed and replicable analysis of methodologic quality.
We did not identify any other systematic reviews of smartphone
applications during the preparation of this review. However,
Kassianos 2015 systematically attempted to identify all available
smartphone applications as of July 2014 by searching the online
stores of smartphone providers (Apple and Android) and then sys-
temically extracting data about the applications from their online
descriptions. Authors made no attempt to identify any diagnostic
test accuracy research underlying the applications. It is notable that
Kassianos 2015 identified 39 applications, and we were only able
to identify test accuracy evaluations for five. We did not contact
developers of commercially available smartphone applications for
any further accuracy data; however, a future review update could
do this.
The main concerns for the review are the clinical applicability of
the findings and exclusion of unevaluable test results, with likely
overestimation of sensitivity.
Applicability of findings to the review question
The data included in this review are unlikely to be generally appli-
cable to the intended setting. Study participants were people who
had skin lesions already scheduled for excision in a dermatology
clinic setting rather than smartphone users with concerns about
a new or changing mole or skin lesion, and dermatologists were
likely to have taken the photographs used with the applications in
the clinic setting in both studies. One study also excluded equiv-
ocal lesions and those with moderate or high-grade atypia, both
of which could potentially be more likely to produce unevaluable
results or be misclassified by the application.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We could not produce any summary estimates of test accuracy
to answer the research question for this review. Smartphone ap-
plications using artificial intelligence-based analysis have not yet
demonstrated sufficient promise in terms of accuracy, and they are
associated with a high likelihood of missing melanomas. Available
data have limited applicability in practice due to selective partic-
ipant recruitment from secondary referral settings and the use of
images not acquired by the intendedusers of the smartphone appli-
cations (i.e. members of the public). Applications based on store-
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and-forward images could have a potential role in the timely pre-
sentation of people with potentially malignant lesions by facilitat-
ing active self-management health practices and early engagement
of those with suspicious skin lesions; however, there are resource
and workload implications with a store-and-forward approach.
Given the paucity of evidence and low methodological quality, we
cannot draw any implications for practice. Nevertheless, this is a
fast-moving field, and new and better apps and better reported
studies could change these conclusions substantially.
Implications for research
Prospective evaluation of smartphone applications for identify-
ing people with suspicious skin lesions who should seek further
medical advice from a suitably qualified clinician is required to
fully understand the accuracy of these tools. Studies should take
place in a clinically relevant community or primary care setting,
recruiting smartphone users who may have concerns about their
risk of developing melanoma or about a new or changing skin le-
sion. Studies might compare the recommendation from the smart-
phone with that of a GP following a face-to-face clinical diagnosis
of the same lesion. In such a study it is important that the GP
assesses all lesions examined using the smartphone in the same
way, with blinding to the smartphone recommendation. Although
histological confirmation of melanoma versus not melanoma is
the ideal reference standard, it is not a practical or ethical one for
study participants with lesions at low risk of malignancy. System-
atic follow-up of non-excised lesions over a five-year period would
avoid over-reliance on a histological reference standard and would
further allow results to be more generalisable to routine practice.
Although a pragmatic evaluation amongst the general population
of smartphone users would be challenging, studies could include
those most at risk of developing melanoma, in whom the preva-
lence of disease would be higher. Use of the test by smartphone
users themselves rather than healthcare professionals or equipment
experts is also key to ensuring the clinical applicability of study
findings and to determine the true test failure rate, which could
seriously inhibit the use of smartphone applications in practice.
Any future research study should conform to the updated Stan-
dards for Reporting of Diagnostic Accuracy (STARD) guideline
(Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Maier 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: not reported
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: patients seen routinely for skin cancer screening at the Department of Derma-
tology
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: not reported
Exclusion criteria: poor quality index test image; (elements in the image not belonging to the lesion
e.g. hair, images containing more than one lesion, incomplete imaged lesions); non-melanocytic
lesions
Also excluded “two-point differences cases” mainly due to inappropriate imaging angle or distance
(we assume this to mean lesions with results in non-consecutive risk classes, e.g. 1 high risk and 2
low risk); and tie cases (described as cases with an equal number of results in two consecutive risk
classes, e.g. 1 high risk, 1 medium risk and 1 low risk result)
Sample size (patients): not reported
Sample size (lesions): no. eligible: 195; no. included: 175 (at least 3 images included per lesion)
Participant characteristics: not reported
Lesion characteristics: not reported
Index tests Mobile phone application
Acquisition and transmission of images: secondary care
Nature of images used: clinical photographs
Any additional patient information provided: unclear if the clinical and dermoscopic diagnosis
was independently documented
Diagnostic threshold: the SkinVision application evaluates lesions to be of high risk (red), medium
risk (yellow) and low risk (green). We classified histologically proven naevi (benign and dysplastic)
as being at low or medium risk
Diagnosis based on: artificial intelligence-based diagnosis
#
In person assessment
Method of diagnosis: visual inspection and dermosocpy
Prior test data: not reported
Diagnostic threshold: diagnosis of melanoma
Diagnosis based on: single observer
Number of examiners: two
Observer qualifications: dermatologist
Experience in practice: unclear - not specified
Experience with index test: unclear - not specified
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Maier 2015 (Continued)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details:
Histology (excision) - 195 eligible lesions including 40 melanomas; 20 lesions excluded due to image
quality (lesion types not reported), leaving 175 lesions analysed by the application (number of
melanomas remaining not reported)
Target condition (final diagnoses)
For the sample of 195: melanoma (in situ or invasive): 40; dysplastic naevi (mild/moderate) 42;
benign naevi 113
For the analysed sample of 175: lesion diagnoses not reported
For the final sample of 144: melanoma (in situ or invasive): 26; dysplastic naevi (mild/moderate)
34; benign naevus: 84
Flow and timing 1. Excluded participants: 20 lesions (10%) excluded due to poor image quality (significant amount
of hair, lesion out of focus or multiple lesions in the focus). An additional 31 were excluded as
unevaluable (13 lesions (6%) based on two-point-differences and 18 (9%) tie cases with an equal
number of results in different risk classes)
2. Time interval to reference test: not reported - assume it is < 1 month as images of the lesions
were taken prior to excision
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Index test
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Maier 2015 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
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Maier 2015 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
High
Wolf 2013
Study characteristics
Patient sampling Study design: case control study
Data collection: retrospective image selection/prospective interpretation
Period of data collection: not reported
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: lesion images selected from the institution image database with specific and
clear histologic diagnoses including: melanoma, melanoma in situ, lentigo, benign naevi (including
compound, junctional and low grade dysplastic naevi), dermatofibroma, sebhorrhoeic keratosis and
haemangioma
Setting: unspecified
Prior testing: selected for excision (no further detail)
Setting for prior testing: unspecified
Exclusion criteria:
Poor quality index test image
Images that contained any identifiable features, such as facial features, tattoos, or labels with patient
information, were excluded or cropped to remove the identifiable features or information
Lesions with specific diagnoses including: Spitz naevi, Reed nevus, uncommon or equivocal lesions;
and lesions with moderate or high-grade atypia
Sample size (patients): not reported
Sample size (lesions): no. eligible 390; no. included 188
Participant characteristics: not reported
Lesion characteristics: not reported
Other: (note: Von Braunmühl 2015 extrapolates sensitivity and specificity to the whole dataset of
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Wolf 2013 (Continued)
195 lesions by including the poor quality index test images - excluded as overlapping populations
with Maier 2015)
Index tests 1. Mobile phone application
Acquisition and transmission of images: secondary care
Nature of images used: not reported
Any additional patient information provided: no further information used
Diagnostic threshold:
Application 1. The application analyses the image and gives an assessment of ’problematic’ (positive
test result) or ’okay’ (negative test result)
Application 2. The output given is ’melanoma’ (positive test result) or ’looks good’ (negative test
result)
Application 3. The output given is ’high risk’ (positive test result) or ’medium risk’ or ’low risk,’
both of which we considered to be a negative test result
Application 4. The dermatologist assigns an output of ’atypical’ (positive test result) or ’typical’
(negative test result); images classified as ’send another photograph’ or ’unable to categorise’ were
considered test failures and excluded by study authors
Observer qualifications (remote diagnosis): application 4 only: images interpreted by a board-
certified dermatologist (n = not reported)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: reference standard details
Histology (not further described) - No. patients/lesions: a total of 188 lesions - disease positive: 60
melanomas - disease negative: 128 benign
Target condition (final diagnoses)
Malignant - melanoma (in situ and invasive): 60
Benign - ’Benign’ diagnoses: 128
Flow and timing 1. Excluded participants: 202/390 lesion images excluded due to poor image quality, containing
identifiable patient information or features, or lacking sufficient clinical or histological information.
Between 3 and 29 additional lesions were analysed by the applications but considered unevaluable
or test failures. The test failure rates were: 3% (n = 6; App 1), 2% (n = 3; App 2), 6% (n = 12; App
3) and 15% (n = 29; App 4)
2. Time interval to reference test: NA
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Wolf 2013 (Continued)
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Index test
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Were the reference standard re-
sults
Unclear
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Wolf 2013 (Continued)
interpreted without knowledge
of the referral diagnosis?
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
High
NA: not applicable.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Braun 2015 Case report
Burki 2013 Not a primary study
Diniz 2016 Inappropriate index test (mobile phone used along with amplifying microscopic lens)
Jahan-Tigh 2016 Inappropriate index test (telediagnosis of ex vivo pathology specimens)
Karargyris 2012 Inappropriate study population
Inappropriate target condition
Lai 2015 Conference abstract
No 2 × 2 data
Massone 2007 Small sample size (< 5 cases of melanoma as final diagnosis)
Inappropriate index test (mobile phone used to capture dermoscopic images)
Ramlakhan 2011 Derivation study (results of the training and test sets not differentiated Table II)
Robson 2012 Inappropriate sample size
Varma 2011 Not a primary study (Editorial)
Von Braunmühl 2015 Duplicate or related publication (Maier 2015)
Wadhawan 2011 Derivation study
Yu 2011 Inappropriate study population
No 2 × 2 data
Zouridakis 2015 Not a primary study (book chapter)
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 App 1 [decision: problematic vs
okay]
1 182
2 App 2 [decision: melanoma vs
not melanoma]
1 185
3 App 3(a) [decision: high risk vs
medium/low risk]
1 170
4 App 3(b) [decision:
high/medium risk vs low risk]
1 170
5 App 4 (remote diagnosis)
[decision: atypical vs typical]
1 159
6 SkinVision [decision: high risk
vs medium/low risk]
1 144
7 Face-to-face dermatologist
diagnosis [decision: melanoma
vs not melanoma]
1 144
Test 1. App 1 [decision: problematic vs okay].
Review: Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma
Test: 1 App 1 [decision: problematic vs okay]
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wolf 2013 42 74 18 48 0.70 [ 0.57, 0.81 ] 0.39 [ 0.31, 0.49 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. App 2 [decision: melanoma vs not melanoma].
Review: Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma
Test: 2 App 2 [decision: melanoma vs not melanoma]
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wolf 2013 40 80 18 47 0.69 [ 0.55, 0.80 ] 0.37 [ 0.29, 0.46 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. App 3(a) [decision: high risk vs medium/low risk].
Review: Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma
Test: 3 App 3(a) [decision: high risk vs medium/low risk]
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wolf 2013 4 7 55 104 0.07 [ 0.02, 0.16 ] 0.94 [ 0.87, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. App 3(b) [decision: high/medium risk vs low risk].
Review: Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma
Test: 4 App 3(b) [decision: high/medium risk vs low risk]
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wolf 2013 32 43 27 68 0.54 [ 0.41, 0.67 ] 0.61 [ 0.52, 0.70 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. App 4 (remote diagnosis) [decision: atypical vs typical].
Review: Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma
Test: 5 App 4 (remote diagnosis) [decision: atypical vs typical]
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wolf 2013 53 73 1 32 0.98 [ 0.90, 1.00 ] 0.30 [ 0.22, 0.40 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. SkinVision [decision: high risk vs medium/low risk].
Review: Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma
Test: 6 SkinVision [decision: high risk vs medium/low risk]
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maier 2015 19 20 7 98 0.73 [ 0.52, 0.88 ] 0.83 [ 0.75, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Face-to-face dermatologist diagnosis [decision: melanoma vs not melanoma].
Review: Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma
Test: 7 Face-to-face dermatologist diagnosis [decision: melanoma vs not melanoma]
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maier 2015 22 3 4 115 0.85 [ 0.65, 0.96 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Index test failures - lesions not evaluable by smartphone application
Study Total number of lesions
(melanomas) successfully assessed
by the each ’app’
Unevaluable lesions (%) Number (%) of unevaluable
melanomas
Wolf 2013
188 lesions
(60 melanomas)a
Application 1 182 (60) 6 (3%) 0 (0%)
Application 2 185 (58) 3 (2%) 2 (3%)
Application 3 170 (59) 12 (6%) 1 (2%)
Application 4 159 (54) 29 (15%) 6 (10%)
Maier 2015
175 lesions
(number of melanomas:
not reported; between26
and 40)b
SkinVision 144 (26) 31 (18%) Not reported (≤ 14)
a52% (202/390) of all images reviewed for inclusion in the study were excluded prior to analysis by the applications.
b10% (20/195) of all images reviewed for inclusion in the study were excluded due to poor image quality or incomplete imaging. The
original sample of 195 lesions included 60 melanomas. The number of melanomas excluded on the basis of image quality and the
number analysed by the application but not included by the study authors (considered as test failures for the purposes of this review)
were not separately reported.
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A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-assisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
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(Continued)
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Glossary of terms
Term Definition
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that may
progress to an invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but non-cancerous mole or area of darker pigmentation of the
skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the
control of cell growth. BRAF mutations (damaged DNA) occur in around 40%
of melanomas, which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents that inhibit the serine-threonine protein kinase BRAFmutated
metastatic melanoma
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a
microscope, measured in mm from the top layer of skin to the bottom of the
tumour
Congenital naevi A type of mole found on infants at birth
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified, ex-
amination of the skin compared to examination by the naked eye alone
False negative An individual who is truly positive for a disease, but whom a diagnostic test
classifies them as disease-free
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them
as having the disease
Histopathology/Hhistology The study of tissue, usually obtained by biopsy or excision, for example under a
microscope
Incidence The number of new cases of a disease in a given time period
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which in-
cludes malignant cells but with no invasive growth. May progress to an invasive
melanoma
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(Continued)
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells)
that travels around the body to help fight disease; they are located throughout the
body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes), also referred to as
moles
Meta-analysis A form of statistical analysis used to synthesise results from a collection of indi-
vidual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the blood-
stream or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a mi-
croscope
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health
Mortality Either the condition of being subject to death; or the death rate, which reflects
the number of deaths per unit of population in relation to any specific region, age
group, disease, treatment or other classification, usually expressed as deaths per
100, 1000, 10,000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g.
urology, oncology, pathology, radiology, and nursing). Cancer care in theNational
Health Service (NHS) uses this system to ensure that all relevant health profes-
sionals are engaged to discuss the best possible care for that patient
Prevalence The proportion of a population found to have a condition
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the
patient’s prognosis
Receiver operating characteristic (ROC) plot A plot of the sensitivity and 1minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a
range of binary test results
Receiver operating characteristic (ROC) analysis The analysis of a ROCplot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can
occur either at the site of the original tumour or at other sites in the body
Reference standard A test or combination of tests used to establish the final or ’true’ diagnosis of a
patient in an evaluation of a diagnostic test
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Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a handheld device or a
static unit) that can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a
disease who have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with
benign skin lesions) who have that absence of disease correctly identified by the
study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into inter-
nationally agreed categories
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or
physical examination
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer
cells throughout the body rather than targeting one specific area
Appendix 3. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
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19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
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71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
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4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
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56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
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4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
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55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
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107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
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#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
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#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
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Database: CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
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S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
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#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
Appendix 4. Full text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
56Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
◦ cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
pigmented skin lesion/nevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscpoy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
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Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLMB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 5. Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Participant selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo
a test should be included in a study, allowing for the intended use of that test within the context of the study. We considered studies that
separately sampled malignant and benign lesions to have used a case-control design; and those that supplemented a series of suspicious
lesions with additional malignant or benign lesions to be at unclear risk of bias.
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion sites, or other
lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion populations,
such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to
contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We considered
studies that include a high number of lesions in relation to the number of participants in the study to be less representative than studies
conducted in a more general population of participants (i.e. if the difference between the number of included lesions and number of
included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to the
result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the original
index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference standard is known;
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however, studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low
risk of bias, we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation.
We also added an item to assess the presence of blinding between interpretations of different algorithms; however, we did not include
this item in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was not data
driven, i.e. was not based on study results. We considered studies that did not clearly describe the threshold used but that required
clinicians to record a diagnosis or management decision for a lesion to be unclear on this criterion. We considered studies reporting
accuracy for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported accuracy for the
presence of independently significant lesion characteristics with no separate test set of lesions, to be at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would be in
real life setting, i.e. tests used and interpreted by the intended users: the general public.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion char-
acteristics that were considered to be indicative for melanoma, particularly where established algorithms or checklists were not used.
Studies were considered of low concern if they used a threshold established in a prior study or presented sufficient threshold detailsto
allow replication.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of
level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial verification bias may
occur where histology is the only reference standard used, and only those participants with a certain degree of suspicion of malignancy
based on the result of the index test undergo verification, the others either being excluded from the study or defined as being disease-
negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious
lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with benign-appearing
lesions but instead follow them up for a period of time to determine whether any malignancy subsequently develops (these would be
false-negatives on the index test). We defined an ’adequate’ reference standard as: all disease-positive individuals having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease-
negative participants have received a histological diagnosis, with up to 20% undergoing at least three months’ follow-up of benign-
appearing lesions.
A further challenge is the potential for incorporation bias, i.e. where the result of the index test is used to help determine the reference
standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on
pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation. Although inclusion
of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation
of the histopathology reference standard is not normal practice, and enforcement of such conditions would significantly limit the
generalisability of the study results. For studies evaluating reflectance confocal microscopy (RCM), we divided this item into two
questions, firstly whether the reference standard was blinded to the index test result (RCM), and secondly whether it was blinded to
the clinical diagnosis. We included only the response to the first part (i.e. blinding to RCM) in our overall assessment of risk of bias for
the reference standard domain.
In judging the applicability of the reference standard to our review question, we scored studies as causing high concern around
applicability if they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report histology
interpretation by a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to each other in
time as possible to avoid changes in lesion over time. For lesions with a histological reference standard, we have defined a one-month
period as an appropriate interval between application of the index test and the reference standard. For studies using clinical follow-
up, we defined a minimum three-month follow-up period as at low risk of bias for detecting false-negatives. This interval was chosen
based on a study showing that most false-negative melanomas will be diagnosed within three months of the initial negative index test,
although a small number will be diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were excluded
following recruitment.
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The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g.
• ’difficult to diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g. ’difficult to diagnose’ lesions, or where disagreement between
evaluators was observed
Unclear - if not clearly reported but there is suspicion that difficult
to diagnose lesions may have been excluded
4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
• A) were the same participant selection criteria used for
those allocated to each test?
• B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A)
• Yes - if same selection criteria were used for each index test,
No - if different selection criteria were used for each index test,
Unclear - if selection criteria per test were not described, NA - if
only 1 index test was evaluated or all participants received all tests
For B)
• Yes - if adequate randomisation procedures are described,
No - if inadequate randomisation procedures are described,
Unclear - if the method of allocation to groups is not described
(a description of ’random’ or ’randomised’ is insufficient), NA -
if only 1 index test was evaluated or all participants received all
tests
For C)
• Yes - if appropriate methods of allocation concealment are
described, No - if appropriate methods of allocation concealment
are not described, Unclear - if the method of allocation
concealment is not described (sufficient detail to allow a definite
judgement is required), NA - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
For non-comparative and within-person-comparative studies
1. If answers to all of questions 1), 2), and 3) ’Yes’
2. If answers to any 1 of questions 1), 2), or 3) ’No’
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’
For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) ’Yes’
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’
For non-comparative and within-person-comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
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(Continued)
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
1) Are the included participants and chosen study setting appro-
priate to answer the review question, i.e. are the study results gen-
eralisable?
• This item is not asking whether exclusion of certain
participant groups might bias the study’s results (as in Risk of
Bias above), but is asking whether the chosen study participants
and setting are appropriate to answer our review question.
Because we are looking to establish test accuracy in both primary
presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be
unclear as to whether the study can appropriately answer either
question
• For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a skin
lesion or B) referred participants, and respond to the questions
in either A) or B) accordingly. If the study gives insufficient
details, please respond Unclear to both parts of the question
A) For studies that will contribute to the analysis of partic-
ipants with a primary presentation of a skin lesion (i.e. test
naive)
Yes - if participants included in the study appear to be generally
representative of those who might present in a usual practice set-
ting
No - if study participants appear to be unrepresentative of usual
practice, e.g. in terms of severity of disease, demographic features,
presence of differential diagnosis or comorbidity, setting of the
study, and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
Yes - if study participants appear to be representative of those who
might be referred for further investigation. If the study focuses
only on those with equivocal lesions, for example, we would sug-
gest that this is not representative of the wider referred population
No - if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1) or 2) ’Yes’
2. If the answer to question 1) or 2) ’No’
3. If the answer to question 1) or 2) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
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No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive (i.e. melanoma present) prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
3) For within-person comparisons of index tests or testing strate-
gies (i.e. > 1 index test applied per participant): was each index
test result interpreted without knowledge of the results of other
index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
NA - if only 1 index test was evaluated
Could the conduct or interpretation of the index test have intro-
duced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1) and 2) ’Yes’
2. If answers to either questions 1) or 2) ’No’
3. If answers to either questions 1) or 2) ’Unclear’
For within-person comparative studies
1. If answers to all questions 1), 2), for any index test and 3)
’Yes’
2. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’No’
3. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’Unclear’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Was the diagnostic threshold to determine presence or absence
of disease established in a previously published study?
e.g. previously evaluated/established
• algorithm/checklist used
• lesion characteristics indicative of melanoma used
• objective (usually numerical) threshold used
Yes - if a previously evaluated/established tool to aid diagnosis
of melanoma was used or if the diagnostic threshold used was
established in a previously published study
No - if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the objective
threshold reportedwas chosenbased on results in the current study
Unclear - if insufficient information was reported
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
Yes - if the criteria for diagnosis of melanoma were reported in
sufficient detail to allow replication
No - if the criteria for diagnosis of melanoma were not reported
in sufficient detail to allow replication
Unclear - if some but not sufficient information on criteria for
diagnosis to allow replication were provided
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3) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in
the use of the test
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported in
sufficient detail to judge or if examiners were described as ’Expert’
with no further detail given
NA - if artificial intelligence-based diagnosis, i.e. no observer in-
terpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1), 2), and 3) ’Yes’
2. If answers to questions 1), 2), or 3) ’No’
3. If answers to questions 1), 2), or 3) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
REFERENCE STANDARD (3) - RISK OF BIAS
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive - 1 or more of the following:
• histological confirmation of melanoma following biopsy or
lesion excision
• clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to a
histological diagnosis of melanoma
B) Disease-negative - 1 or more of the following:
• histological confirmation of absence of melanoma
following biopsy or lesion excision in at least 80% of disease-
negative participants
• clinical follow-up of benign-appearing lesions for a
minimum of 3 months following the index test in up to 20% of
disease-negative participants
A) Disease-positive
Yes - if all participants with a final diagnosis of melanoma under-
went 1 of the listed reference standards
No - If a final diagnosis of melanoma for any participant was
reached without histopathology
Unclear - if the method of final diagnosis was not reported for
any participant with a final diagnosis of melanoma or if the length
of clinical follow-up used was not clear or if a clinical follow-up
reference standard was reported in combination with a partici-
pant-based analysis and it was not possible to determine whether
the detection of a malignant lesion during follow-up is the same
lesion that originally tested negative on the index test
B) Disease-negative
Yes - If at least 80% of benign diagnoses were reached by histology
and up to 20% were reached by clinical follow-up for a minimum
of 3 months following the index test
No - ifmore than20%of benigndiagnoseswere reachedby clinical
follow-up for a minimum of 3 months following the index test or
if clinical follow-up period was less than 3 months
Unclear - if the method of final diagnosis was not reported for
any participant with benign or non-melanoma diagnosis
2) Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
Yes - if the reference standard diagnosis was reached blinded to
the index test result
No - if the reference standard diagnosis was reached with knowl-
edge of the index test result
Unclear - if blinded reference test interpretation was not clearly
reported
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tests, this item will be retained
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1) ’Yes’
2. If answer to question 1) ’No’
3. If answer to question 1) ’Unclear’
For all other tests
1. If answers to questions 1) and 2) ’Yes’
2. If answers to questions 1) or 2) ’No’
3. If answers to questions 1) or 2) ’Unclear’
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Are index test results presented separately for each component
of the target condition (i.e. separate results presented for those
with invasivemelanoma,melanoma in situ, lentigomaligna, severe
dysplasia, BCC, and cSCC)?
Yes - if index test results for each component of the target condition
can be disaggregated
No - if index test results for the different components of the target
condition cannot be disaggregated
Unclear - if not clearly reported
2) Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes - if expert opinion was not used as a reference standard for
any participant
No - if expert opinion was used as a reference standard for any
participant
Unclear - if not clearly reported
3) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to all questions 1), 2), and 3) ’Yes’
2. If answers to any 1 of questions 1), 2), or 3) ’No’
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’
***For teledermatology studies only
1. If answers to all questions 1) and 3) ’Yes’
2. If answers to questions 1) or 3) ’No’
3. If answers to questions 1) or 3) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
***For teledermatology studies only
1. Concern is low
2. Concern is high
3. Concern is unclear
FLOW AND TIMING (4):RISK OF BIAS
1) Was there an appropriate interval between index test and ref-
erence standard?
A) For histopathological reference standard, was the interval be-
A)
Yes - if study reports ≤ 1 month between index and reference
standard
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tween index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 3 months’ follow-
up following application of index test(s)?
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
B)
Yes - if study reports ≥ 3 months’ follow-up
No - if study reports < 3 months’ follow-up
Unclear - if study does not report the length of clinical follow-up
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear- if not clearly reported
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report the interval between index tests
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1), 2), and 3) ’Yes’
2. If answers to any 1 of questions 1), 2), or 3) ’No’
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’
For within-person comparative studies
1. If answers to all questions 1), 2), 3), and 4) ’Yes’
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the primary objectives and primary target condition from detection of cutaneous invasive melanoma alone, to the detection
of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants, as the latter is more clinically relevant in practice.
We also amended the primary objective from “To determine the diagnostic accuracy of smartphone applications for the detection
of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants in adults when used by consumers” to “To assess
the diagnostic accuracy of smartphone applications to rule out cutaneous invasive melanoma and atypical intraepidermal melanocytic
variants in adults with concerns about suspicious skin lesions” in order to better reflect the intended role of smartphone applications.
Due to lack of data, we did not investigate secondary objectives related to the detection of any skin cancer or skin lesion with a high
risk of progression to melanoma or the original primary objective related to detection of invasive melanoma alone.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
To improve clarity of methods, we replaced the following text from the protocol: “We will include studies developing new algorithms
or methods of diagnosis (i.e. derivation studies) if they use a separate independent ’test set’ of participants or images to evaluate the
new approach. We will also include studies using other forms of cross validation, such as ’leave-one-out’ cross-validation (Efron 1983).
We will note for future reference (but not extract) any data on the accuracy of lesion characteristics individually, e.g. the presence or
absence of a pigment network or detection of asymmetry.”
This section now reads as follows.
“We included studies developing new mobile phone applications (i.e. derivation studies) if they used a separate independent ’test set’
of participants or images to evaluate the new approach.
”We excluded studies if they:
• used a statistical model to produce a data-driven equation or algorithm based on multiple diagnostic features, with no separate
test set;
• used cross-validation approaches such as ’leave-one-out’ cross-validation (Efron 1983); or
• evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no overall
diagnosis of malignancy.“
As per the secondary objectives above, we have removed the target conditions of invasive melanoma alone and of any skin cancer or
skin lesion with a high risk of progression to melanoma from the review due to lack of data.
We added a clarification to the Index tests section that smartphone app use by clinicians for a second opinion by specialists is covered
in teledermatology, whereas this review covers applications intended for use by the general public.
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We planned to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology); however, due to the volume of evidence retrieved from database searches and time restrictions we were unable to do this.
For quality assessment, we further tailored the QUADAS-2 tool according to the review topic.
In terms of analysis, we could not restrict analysis to per patient data due to lack of data. For the same reason, we could not investigate
heterogeneity or perform sensitivity analyses.
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